Project Description

Study Title: A Phase 2b, Multi-Center, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess the Immunological Response and Safety Profile of a Single Dose BPZE1 With and Without Co-Administration of Tetanus, Diphtheria, and Acellular Pertussis (Boostrix™)

Chief Medical Officer and Executive VP of Clinical Research: Cheryl Keech, MD, PhD ILiAD Biotechnologies

Sponsor: ILiAD Biotechnologies

Oxus Technologies provided data management services for the IB-201P clinical study, sponsored by ILiAD Biotechnologies, LLC. Support included database design, validation planning, and data oversight throughout the study.